Fortrea (NASDAQ:FTRE) (NASDAQ:FTRE) is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company delivers end-to-end solutions encompassing process development, clinical and commercial manufacturing, analytical testing and regulatory support. Fortrea’s integrated service offerings are designed to accelerate the development and supply of small-molecule and biologic therapies, helping clients navigate complex regulatory pathways and meet evolving market demands.
Fortrea’s capabilities span the full life cycle of drug development. In the small-molecule arena, the company provides synthetic chemistry, formulation development, scale-up and cGMP commercial manufacturing. For biologics, Fortrea offers cell line development, upstream and downstream processing, aseptic fill-finish and packaging services. Its analytical laboratories perform method development, stability studies and release testing, while regulatory experts guide submissions and inspections in key markets.
Formed in 2022 through the consolidation of several established CDMO platforms under the ownership of New Mountain Capital, Fortrea has rapidly expanded its global footprint. The company operates a network of facilities across North America, Europe and Asia, including major sites in the United States, Switzerland, Spain and India. This geographic reach enables Fortrea to support both early-stage clinical trials and large-scale commercial production, ensuring reliable supply chains for its customers worldwide.
Under the leadership of CEO Christopher Cline and a senior management team drawn from industry veterans, Fortrea is focused on strategic investments in capacity, technology and digital infrastructure. By leveraging its multidisciplinary expertise and flexible operating model, the company aims to deliver tailored solutions for emerging therapies, orphan drugs and blockbuster pharmaceuticals alike, reinforcing its position as a trusted partner in the life sciences sector.
